Combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin

A fibronectin and growth factor technology, applied in the field of medical testing, can solve problems such as judgment that affects the measurement results, test strips are easily contaminated, etc., to improve compliance, reduce the probability of uterine contractions or infection, and operate quickly and easily. Effect

Active Publication Date: 2022-02-11
ANHUI HUIBANG BIOLOGICAL ENG
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] (3) This solution is a naked test strip and is observed with the naked eye. The test strip is easily contaminated, which affects the judgment of the measurement result

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin
  • Combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin
  • Combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0049] The preferred embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings, so that the advantages and features of the present invention can be more easily understood by those skilled in the art, so as to define the protection scope of the present invention more clearly.

[0050] see figure 1 and figure 2 , the embodiment of the present invention includes:

[0051] A combined quantitative detection system for the contents of insulin-like growth factor binding protein-1 (IGFBP-1) and fetal fibronectin (fFN), including a kit and detection equipment. The detection equipment is used for the quantitative detection of the two proteins in the kit, and provides a reference for diagnosing premature rupture of membranes and predicting premature delivery. Preferably, the detection equipment adopts HR201 colloidal gold test paper analyzer.

[0052] The kit mainly includes a test card 1, a standard curve comparison table, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin, including a kit and detection equipment; the kit uses double-antibody sandwich immunochromatography technology, and supporting instruments It is used to realize the quantitative detection of insulin-like growth factor-binding protein-1 and fetal fibronectin in vaginal secretions or vaginal effusions of pregnant women, and provides a reference for diagnosing premature rupture of membranes and predicting premature delivery. Also disclosed is a preparation method of a gold-labeled pad for simultaneously measuring the contents of insulin-like growth factor-binding protein-1 and fetal fibronectin and the prepared gold-labeled pad. The gold-labeled pad adopts two kinds of antibodies to label colloidal gold and mix The gold-spraying method of the reconstituted solution realizes the simultaneous detection of two proteins, realizes the quantitative detection of two indicators at the same time in one sampling, the operation is fast and simple, and the detection accuracy is high.

Description

technical field [0001] The invention relates to the field of medical detection, in particular to a combined quantitative detection system for the content of insulin-like growth factor binding protein-1 and fetal fibronectin. Background technique [0002] The rupture of membranes before labor is called premature rupture of membranes (PROM), and the premature rupture of membranes at <37 weeks of gestation is also called premature (not term) premature rupture of membranes. Premature rupture of membranes is the most common perinatal complication, which can lead to increased rates of premature birth, increased perinatal mortality, increased rates of intrauterine infection and puerperal infection, and premature rupture of membranes after 37 weeks of pregnancy The incidence of premature rupture of membranes is about 10%, and the incidence of premature rupture of membranes less than 37 weeks of pregnancy is about 2.0% -3.5%. PROM can be complicated by premature delivery, umbilic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/532G01N33/558
CPCG01N33/689G01N33/6872G01N33/532G01N33/558
Inventor 胡容王忠亮
Owner ANHUI HUIBANG BIOLOGICAL ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap